Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving the 5-year overall survival rate and decrease the peritoneal metastases rate of patients with advanced gastric cancer underwent Laparoscopic Gastrectomy with D2 Lymphadenectomy. Participants will be divided into two groups, Experimental group received laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6\~8 cycles; and Control group received laparoscopic (robotic) D2 surgery plus systemic chemotherapy 6\~8 cycles.

NCT Number	NCT05871099
Lead Sponsor	The Affiliated Hospital of Qingdao University Collaborators: Shandong Cancer Hospital and Institute, Chinese PLA General Hospital, Zibo Central Hospital, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Jinan Central Hospital, Qilu Hospital of Shandong University, Yantai Yuhuangding Hospital, Nanfang Hospital, Southern Medical University, Shandong First Medical University, The First Affiliated Hospital of Nanchang University, Hebei Medical University Fourth Hospital, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Tianjin Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhongnan Hospital, Brigham and Women's Hospital, Second Xiangya Hospital of Central South University, Weihai Municipal Hospital, Mountain University Cancer Hospital, Ruijin Hospital
Conditions	Gastric Cancer
Enrollment	616 participants
Start Date	2022-11-20
Primary Completion	2030-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-06